Christopher LeMasters

Xinthera's Board of Directors has appointed Christopher LeMasters as the company’s first Chief Executive Officer. LeMasters, who has served as the company’s EVP and Chief Operating Officer since October 2021, was also appointed to XinThera’s Board of Directors.

Over his 30-year career, Mr. LeMasters has co-founded and served as a management team member for multiple biotechnology companies. Prior to serving as COO of XinThera, he was COO of Amplyx Pharmaceuticals, where he led the strategic efforts that resulted in the company’s successful sale to Pfizer in April 2021. From 2016 to 2020, Mr. LeMasters was EVP & CBO of Mirati Therapeutics, where he was responsible for corporate development, strategy, and investor relations. He also served as the CEO of Promosome, a privately held mRNA re-engineering company, and as CBO at Conforma Therapeutics, Cabrellis Therapeutics, and Tragara Pharmaceuticals. Earlier in his career, he worked in the corporate business development group at Eli Lilly & Company and as a management consultant with Coopers & Lybrand and Owens-Corning.

Mr. LeMasters holds a BS in Finance from Indiana University and an MBA from the University of Chicago.